Imricor Medical Systems has initiated its first MRI-guided atrial flutter ablation procedures at Semmelweis University in Budapest, marking a significant expansion of its real-time MRI technology in Europe.
Neurizon Therapeutics reports encouraging 8-month interim results for its ALS drug NUZ-001, secures Orphan Medicinal Product Designation in Europe, and raises $885,000 through a share placement, maintaining a robust $14 million cash position.